Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Organisation › Details

UCB S.A. (Euronext: UCB)

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB). *

 

Period Start 1928-01-01 established
  Group UCB (Group)
Products Industry pharmaceutical
  Industry 2 CNS drug
Person Person Tellier, Jean-Christophe (201403– CEO-elect joined UCB 2011 before Ipsen + Macrogenics + Novartis)
     
Region Region Brussels
  Country Belgium
  Street 60 Allée de la Recherche
  City 1070 Brussels
  Tel +32-2-559-9999
    Address record changed: 2018-07-24
     
Basic data Currency EUR
  Annual sales 4,632,000,000 (revenue, consolidated (2018) 2018-12-31)
  Profit 823,000,000 (2018-12-31)
  Cash 1,049,000,000 (2017-12-31)
     
    * Document for �About Section�: Activiomics Ltd.. (12/6/10). "Press Release: Activiomics Signs Technology Agreement with UCB".
     
   
Record changed: 2019-04-19

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for UCB (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top